Deximune 100 mg soft capsules
4.1 Therapeutic indications
Transplantation Indications
Solid Organ Transplantation
Prevention of graft rejection following solid organ transplantation.
Treatment of transplant rejection in patients previously receiving other immunosuppressive agents.
Bone Marrow Transplantation
Prevention of graft rejection following allogeneic bone marrow and stem cell transplantation.
Prevention or treatment of graft-versus-host disease (GVHD).
Non-Transplantation Indications
Endogenous uveitis
Treatment of sight-threatening intermediate or posterior uveitis of non-infectious aetiology in patients in whom conventional therapy has failed or caused unacceptable side effects.
Treatment of Behçet uveitis with repeated inflammatory attacks involving the retina in patients without neurological manifestations.
Psoriasis
Deximune Capsules are indicated in patients with severe psoriasis in whom conventional therapy is ineffective or inappropriate.
Atopic Dermatitis
Deximune Capsules are indicated in patients with severe atopic dermatitis when systemic therapy is required.
Rheumatoid Arthritis
Deximune Capsules are indicated for the treatment of severe, active rheumatoid arthritis.
Nephrotic Syndrome
Steroid-dependent and steroid-resistant nephrotic syndrome due to primary glomerular diseases such as minimal change nephropathy, focal segmental glomerulosclerosis or membranous glomerulonephritis.
Deximune Capsules can be used to induce remissions and for maintenance remissions. It can also be used to maintain steroid-induced remission, allowing withdrawal of steroids.
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest
Disclaimer
The drug SPC information (indications, contra-indications, interactions, etc), has been developed in collaboration with eMC (www.medicines.org.uk/emc/). Medthority offers the whole library of SPC documents from eMC.
Medthority will not be held liable for explicit or implicit errors, or missing data.
Drug Licencing
Drugs appearing in this section are approved by UK Medicines & Healthcare Products Regulatory Agency (MHRA), & the European Medicines Agency (EMA).